Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12328005 | 0.89 | SCN10A (0.36) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL18071378 | 0.82 | SCN10A (0.34) | SCN10A | |
| SCHEMBL882760 | 0.82 | MAPK13 (0.41) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10201775 | 0.81 | SCN10A (0.52) | SCN10A | |
| SCHEMBL14758535 | 0.80 | SCN10A (0.39) | SCN10A | |
| SCHEMBL10144768 | 0.79 | SCN10A (0.51) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL16572630 | 0.79 | SCN10A (0.51) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL16405116 | 0.79 | SCN10A (0.51) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10201771 | 0.77 | SCN10A (0.37) | SCN10A | |
| SCHEMBL15373033 | 0.77 | HPGDS (0.35) | SCN10AMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414350-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-12 | — | — | EP | disclosed |
| WO-2012039717-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| WO-2010117635-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | SCN10A 4305/4885MAPK13 1290/4885MAPK12 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.